Table 1.
Select immunotherapies under clinical evaluation for GBM.
| Class | Company | Treatment | Target | Phase | Identifier |
|---|---|---|---|---|---|
|
| |||||
| Peptide vaccines | Stemline Therapeutics |
SL-701 | IL-13Rα, EphA2, survivin | I/II | NCT02078648 |
| Agenus | HSPPC-96 | heat shock protein | II | NCT01814813 | |
| Epitopoietic | ERC-1671 | Tumor lysate and cells from 3 donor patients | II | NCT01903330 | |
|
| |||||
| DC vaccines | – | CMV-specific DCs | CMV antigen pp65 | II | NCT02366728 |
| Northwest Biotherapeutics | DC-VaxL | Antigens derived from patient tumor | III | NCT00045968 | |
| – | DCs pulsed with tumor lysate | Antigens derived from patient tumor | II | NCT01204684 | |
| ImmunoCellular Therapeutics/Targepeutics | ICT107 | HER2, TRP-2, gp100, MAGE-1, IL-13Rα, AIM-2 | II | NCT01280552 | |
|
| |||||
| Checkpoint inhibitors | Tracon Pharmaceuticals/Santen | TRC105 | endoglin | I/II | NCT01648348 |
|
| |||||
| Gilead Sciences | Ipilimumab | CTLA-4 PD-1 VEGF |
III | NCT02017717 | |
|
| |||||
| Ono Pharmaceutical/Bristol-Myers Squibb | Nivolumab | ||||
|
| |||||
| – | Bevacizumab | ||||
|
| |||||
| CureTech/Medivation/Teva | Pidilizumab | PD-1 | I/II | NCT01952769 | |
|
| |||||
| Ipilimumab Nivolumab |
CTLA-4 PD-1 |
I | NCT02311920 | ||
|
| |||||
| Adoptive transfer | – | CAR T Cells | EGFRvIII | I/II | NCT01454596 |
| – | CAR T Cells | IL-13Rα2 | I | NCT02208362 | |
| – | CAR T Cells | Her2 | I | NCT01109095 | |
|
| |||||
| Oncolytic virotherapy | VectorLogics (now DNAtrix) | DNX2401 | Tumor selective adenovirus | I | NCT01956734 |
| Virttu | HSV1716 | Tumor selective herpes simplex virus | I | NCT02031965 | |
| DNX2401 | Tumor selective adenovirus | I | NCT02197169 | ||
| – | PVSRIPO | Tumor selective poliovirus | I | NCT01491893 | |